Pharma BD Deal Intelligence

Astellas Pharma Inc. / OSI Pharmaceuticals, Inc.

2010 · Acquisition/Merger · $4.0B · Complete

Astellas agreed to acquire OSI Pharmaceuticals for $57.50/share cash, totaling ~$4.0B. Closed June 9, 2010, providing Astellas a U.S. oncology platform anchored by Tarceva.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced May 16, 2010
Closed Jun 09, 2010
Deal value $4.0B
Deal type Acquisition/Merger
Therapeutic area Non-small cell lung cancer; pancreatic cancer
Indications Non-small cell lung cancer; pancreatic cancer
Key assets Tarceva (erlotinib)
Mechanism EGFR tyrosine kinase inhibitor

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals